{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:02:09Z","timestamp":1770573729463,"version":"3.49.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"Valeant Pharmaceuticals International Inc"},{"name":"Anacor Pharmaceuticals Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.2217\/fmb.14.76","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T16:36:11Z","timestamp":1417451771000},"page":"1243-1250","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Potential Role of Tavaborole for the Treatment of Onychomycosis"],"prefix":"10.1080","volume":"9","author":[{"given":"Aditya K","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, ON, Canada"},{"name":"Mediprobe Research, Inc., London, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanne","family":"Daigle","sequence":"additional","affiliation":[{"name":"Mediprobe Research, Inc., London, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,12]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-011-9402-1"},{"issue":"2","key":"e_1_3_2_4_1","first-page":"105","article-title":"Pattern of onychomycosis \u2013 a RIMS study","volume":"43","author":"Pukhrambam PD","year":"2011","unstructured":"Pukhrambam PD , DeviKR , SinghNB . Pattern of onychomycosis \u2013 a RIMS study . J. Commun. Dis.43 ( 2 ), 105 \u2013 112 ( 2011 ).","journal-title":"J. Commun. Dis."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05509.x"},{"issue":"3","key":"e_1_3_2_6_1","first-page":"350","article-title":"Frequency of Candida in onychomycosis","volume":"63","author":"Ahmed R","year":"2013","unstructured":"Ahmed R , KharalSA , DurraniMA , SabirM , ChangAH , Fakharuddin . Frequency of Candida in onychomycosis . J. Pak. Med. Assoc.63 ( 3 ), 350 \u2013 353 ( 2013 ).","journal-title":"J. Pak. Med. Assoc."},{"issue":"2","key":"e_1_3_2_7_1","first-page":"250","article-title":"The prevalence of fungi in fingernail onychomycosis","volume":"7","author":"Gelotar P","year":"2013","unstructured":"Gelotar P , VachhaniS , PatelB , MakwanaN . The prevalence of fungi in fingernail onychomycosis . J. Clin. Diagn. Res.7 ( 2 ), 250 \u2013 252 ( 2013 ).","journal-title":"J. Clin. Diagn. Res."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.7547\/0003-0538-104.4.330"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2012.10.002"},{"issue":"3","key":"e_1_3_2_10_1","first-page":"320","article-title":"The incidence of onychomycosis infection among patients referred to hospitals in Kermanshah province, Western Iran","volume":"42","author":"Mikaeili A","year":"2013","unstructured":"Mikaeili A , KarimiI . The incidence of onychomycosis infection among patients referred to hospitals in Kermanshah province, Western Iran . Iran J. Public Health42 ( 3 ), 320 \u2013 325 ( 2013 ).","journal-title":"Iran J. Public Health"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.0014"},{"issue":"1","key":"e_1_3_2_12_1","first-page":"37","article-title":"Onychomycosis: an Asian perspective","volume":"8","author":"Sehgal VN","year":"2010","unstructured":"Sehgal VN , SrivastavaG , DograS , ChaudharyA , AdhikariT . Onychomycosis: an Asian perspective . Skinmed8 ( 1 ), 37 \u2013 45 ( 2010 ).","journal-title":"Skinmed"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2010.00678.x"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.547879"},{"issue":"11","key":"e_1_3_2_16_1","first-page":"1263","article-title":"Onychomycosis: burden of disease and the role of topical antifungal treatment","volume":"12","author":"Daniel RC","year":"2013","unstructured":"Daniel RC . Onychomycosis: burden of disease and the role of topical antifungal treatment . J. Drugs Dermatol.12 ( 11 ), 1263 \u2013 1266 ( 2013 ).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.011"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.010"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05242.x"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01284.x"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01351.x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.730"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3797-3801.2002"},{"key":"e_1_3_2_24_1","unstructured":"Valeant Pharmaceuticals International Inc. Valeant Pharmaceuticals announces approval of Jubila\u00ae for treatment of onychomycosis in Canada ( 2013 ). http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Approval-Of-Jublia-For-The-Treatment-Of-Onychomycosis-In-Canada\/default.aspx ."},{"key":"e_1_3_2_25_1","unstructured":"Valeant Pharmaceuticals Inc . Valeant Pharmaceuticals Announces FDA Approval Of Jublia\u00ae for the Treatment of Onychomycosis ( 2014 ). http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2014\/Valeant-Pharmaceuticals-Announces-FDA-Approval-Of-Jublia-for-the-Treatment-of-Onychomycosis\/default.aspx ."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.840289"},{"key":"e_1_3_2_27_1","unstructured":"Celtic Pharma Development Services . TDT 067 onychomycosis study ( 2012 ). www.clinicaltrials.gov\/ct2\/show\/NCT01145807 ."},{"key":"e_1_3_2_28_1","unstructured":"Topica Pharmaceuticals . Safety and efficacy of luliconazole solution 10% in subjects with mild to moderate onychomycosis ( 2013 ). www.clinicaltrials.gov\/ct2\/show\/NCT01431820 ."},{"key":"e_1_3_2_29_1","unstructured":"Anacor Pharmaceuticals Inc. Efficacy and safety of AN2690 topical solution to treat onychomycosis of the toenail ( 2013 ). www.clinicaltrials.gov\/ct2\/show\/NCT01302119 ."},{"key":"e_1_3_2_30_1","unstructured":"Anacor Pharmaceuticals Inc . FDA approves Anacor Pharmaceuticals\u2019 KERYDIN\u2122 (tavaborole) topical solution 5% for the treatment of onychomycosis of the toenails ( 2014 ). http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=858211 ."},{"key":"e_1_3_2_31_1","unstructured":"Sanders V BakerSJ AlleyMRKet al. Microbiological activity of AN2690 a new antifungal agent in development for the topical treatment of onychomycosis ( 2013 ). www.anacor.com\/pdf\/AAD_P1608.pdf ."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20901"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603724"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80305-8"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00025-1"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142189"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.04.073"},{"key":"e_1_3_2_38_1","unstructured":"Beutner KR SandersV HoldK BullingtonR MaplesK JonesT . An open-label multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis ( 2007 ). www.anacor.com\/pdf\/poster_1823.pdf ."},{"key":"e_1_3_2_39_1","unstructured":"Hold KM BuW SandersV JonesT BeutnerK . In vivo nail residence time of AN2690 a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis ( 2007 ). www.anacor.com\/pdf\/poster_1816.pdf ."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02056-12"},{"key":"e_1_3_2_41_1","unstructured":"Anacor Pharmaceuticals Inc . Absorption and systemic study of AN2690 in patients withmoderate to severe onychomycosis (ADME II) ( 2008 ). www.clinicaltrials.gov\/ct2\/show\/NCT00679601 ."},{"key":"e_1_3_2_42_1","unstructured":"Zane L PollakR . Safety and efficacy of tavaborole (formerly AN2690) a novel boron-based molecule in Phase 2 trials for the topical treatment of toenail onychomycosis ( 2012 ). www.anacor.com\/pdf\/APMA%20Tavaborole%20Phase%202%20Poster.pdf ."},{"key":"e_1_3_2_43_1","unstructured":"Anacor Pharmaceuticals Inc . Study ofdifferent doses of a novel treatment for onychomycosis ( 2012 ). www.clinicaltrials.gov\/ct2\/show\/NCT00679965 ."},{"key":"e_1_3_2_44_1","unstructured":"Anacor Pharmaceuticals Inc . Safety and efficacy study of subjects with onychomycosis of the great toenail ( 2008 ). www.clinicaltrials.gov\/ct2\/show\/NCT00679523 ."},{"key":"e_1_3_2_45_1","unstructured":"Anacor Pharmaceuticals Inc . Safety and efficacy studyof subjects with onychomycosis of the great toenail ( 2013 ). www.clinicaltrials.gov\/ct2\/show\/NCT01278394 ."},{"key":"e_1_3_2_46_1","unstructured":"Anacor Pharmaceuticals Inc . Safety and efficacy evaluation of topically applied AN2690 solutions for subjects with onychomycosis ( 2008 ). www.clinicaltrials.gov\/ct2\/show\/NCT00680134 ."},{"key":"e_1_3_2_47_1","unstructured":"Elewski BE RichP WiltzHet al. Effectiveness and safety of tavaborole a novel boron-based molecule for the treatment of onychomycosis: results from two Phase 3 studies ( 2013 ). www.anacor.com\/pdf\/Tavaborole_Phase%203%20Poster_Final%20Copy_093013.pdf ."},{"key":"e_1_3_2_48_1","unstructured":"Anacor Pharmaceuticals Inc . Efficacy and safety evaluation of AN2690 topical solution to treat onychomycosis of the toenail ( 2013 ). www.clinicaltrials.gov\/ct2\/show\/NCT01270971 ."},{"key":"e_1_3_2_49_1","unstructured":"Ip E SandersV BakerS Bellinger-KawaharaC MaplesK . Preclinical toxicology of AN2690 a new antifungal agent in development for the topical treatment of onychomycosis ( 2006 ). www.anacor.com\/pdf\/AAD_P1611.pdf ."},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.21779"},{"key":"e_1_3_2_51_1","unstructured":"Chanda S LiuL HeymanI . Preclinical safety studies with AN2690 a novel boron-containing small molecule for topical treatment of onychomycosis demonstrate promising safety profile (Internet) ( 2011 ). www.anacor.com\/pdf\/ESDR_AN2690_223.pdf ."},{"issue":"2","key":"e_1_3_2_52_1","first-page":"AB124","article-title":"Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solution for the treatment of onychomycosis of the great toenail","volume":"56","author":"Beutner KR","year":"2007","unstructured":"Beutner KR , Toledo-BahenaM , Mata-LaraM , LeanoA , Barbosa-AlanisH . Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solution for the treatment of onychomycosis of the great toenail . J. Am. Acad. Dermatol.56 ( 2 ), AB124 ( 2007 ).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_2_53_1","unstructured":"Anacor Pharmaceuticals Inc . Pipeline ( 2011 ). www.anacor.com\/pipeline_overview.php ."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.14.76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:22Z","timestamp":1719124702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.14.76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.2217\/fmb.14.76"],"URL":"https:\/\/doi.org\/10.2217\/fmb.14.76","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}